BIOMARKER:

BAP1 mutation

Entrez ID:

Related biomarkers:

‹

›

BAP1 mutation BAP1 mutation	Mesothelioma Mesothelioma	BAP1 mutation BAP1 mutation	Mesothelioma Mesothelioma	tazemetostat Sensitive: C2 – Inclusion Criteria	tazemetostat Sensitive: C2 – Inclusion Criteria
BAP1 mutation BAP1 mutation	Urothelial Cancer Urothelial Cancer	BAP1 mutation BAP1 mutation	Urothelial Cancer Urothelial Cancer	olaparib Sensitive: C2 – Inclusion Criteria	olaparib Sensitive: C2 – Inclusion Criteria
BAP1 mutation BAP1 mutation	Melanoma Melanoma	BAP1 mutation BAP1 mutation	Melanoma Melanoma	vorinostat Sensitive: C2 – Inclusion Criteria	vorinostat Sensitive: C2 – Inclusion Criteria
BAP1 mutation BAP1 mutation	Mesothelioma Mesothelioma	BAP1 mutation BAP1 mutation	Mesothelioma Mesothelioma	olaparib Resistant: C3 – Early Trials	olaparib Resistant: C3 – Early Trials
BAP1 mutation BAP1 mutation	Cholangiocarcinoma Cholangiocarcinoma	BAP1 mutation BAP1 mutation	Cholangiocarcinoma Cholangiocarcinoma	cisplatin + gemcitabine Resistant: C3 – Early Trials	cisplatin + gemcitabine Resistant: C3 – Early Trials
BAP1 mutation BAP1 mutation	Renal Cell Carcinoma RCC	BAP1 mutation BAP1 mutation	Renal Cell Carcinoma RCC	everolimus Resistant: C3 – Early Trials	everolimus Resistant: C3 – Early Trials
BAP1 mutation BAP1 mutation	Renal Cell Carcinoma RCC	BAP1 mutation BAP1 mutation	Renal Cell Carcinoma RCC	Tyrosine kinase inhibitor Resistant: C3 – Early Trials	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
BAP1 mutation BAP1 mutation	Mesothelioma Mesothelioma	BAP1 mutation BAP1 mutation	Mesothelioma Mesothelioma	rucaparib Sensitive: C3 – Early Trials	rucaparib Sensitive: C3 – Early Trials
BAP1 mutation BAP1 mutation	Renal Cell Carcinoma RCC	BAP1 mutation BAP1 mutation	Renal Cell Carcinoma RCC	Glutamate inhibitor Sensitive: D – Preclinical	Glutamate inhibitor Sensitive: D – Preclinical
BAP1 mutation BAP1 mutation	Uveal Melanoma Uveal Melanoma	BAP1 mutation BAP1 mutation	Uveal Melanoma Uveal Melanoma	JNJ 26481585 Sensitive: D – Preclinical	JNJ 26481585 Sensitive: D – Preclinical
BAP1 mutation BAP1 mutation	Solid Tumor Solid Tumor	BAP1 mutation BAP1 mutation	Solid Tumor Solid Tumor	BET inhibitor Sensitive: D – Preclinical	BET inhibitor Sensitive: D – Preclinical